Mizuho reiterated their buy rating on shares of Concert Pharmaceuticals (NASDAQ:CNCE) in a research report report published on Friday, AnalystRatings.com reports. The firm currently has a $18.00 price target on the biotechnology company’s stock.
CNCE has been the topic of a number of other reports. SunTrust Banks dropped their price target on Concert Pharmaceuticals from $30.00 to $20.00 and set a buy rating on the stock in a research note on Monday, September 30th. HC Wainwright dropped their price target on Concert Pharmaceuticals from $29.00 to $25.00 and set a buy rating on the stock in a research note on Thursday, October 3rd. Zacks Investment Research downgraded Concert Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, October 1st. Janney Montgomery Scott reaffirmed a buy rating and set a $10.00 price target (down from $13.00) on shares of Concert Pharmaceuticals in a research note on Monday, September 30th. Finally, ValuEngine downgraded Concert Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, November 4th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $15.63.
Shares of Concert Pharmaceuticals stock traded up $0.21 on Friday, hitting $6.94. 153,848 shares of the company’s stock traded hands, compared to its average volume of 223,432. Concert Pharmaceuticals has a one year low of $5.36 and a one year high of $17.83. The company has a debt-to-equity ratio of 0.12, a current ratio of 19.63 and a quick ratio of 19.63. The company has a fifty day moving average of $6.61 and a two-hundred day moving average of $9.73. The company has a market capitalization of $152.32 million, a price-to-earnings ratio of -2.89 and a beta of 0.88.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.13. Concert Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 7,303.34%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.35 million. Equities research analysts anticipate that Concert Pharmaceuticals will post -3.45 earnings per share for the current year.
In related news, Director Heek Christi Van acquired 5,000 shares of the stock in a transaction dated Tuesday, October 8th. The stock was purchased at an average cost of $5.90 per share, with a total value of $29,500.00. Following the completion of the purchase, the director now directly owns 5,000 shares in the company, valued at approximately $29,500. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 11.00% of the company’s stock.
Several institutional investors have recently modified their holdings of CNCE. Quantamental Technologies LLC purchased a new stake in shares of Concert Pharmaceuticals during the second quarter valued at approximately $27,000. Flagship Harbor Advisors LLC increased its position in shares of Concert Pharmaceuticals by 163.2% during the third quarter. Flagship Harbor Advisors LLC now owns 5,000 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,100 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of Concert Pharmaceuticals during the second quarter valued at approximately $43,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Concert Pharmaceuticals during the second quarter valued at approximately $128,000. Finally, Parametric Portfolio Associates LLC increased its position in shares of Concert Pharmaceuticals by 10.6% during the second quarter. Parametric Portfolio Associates LLC now owns 11,349 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 1,089 shares during the last quarter. 70.89% of the stock is owned by hedge funds and other institutional investors.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Featured Article: What is a stock split?
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.